Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 at Barclays

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price raised by Barclays from $35.00 to $37.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other analysts also recently issued reports on SNDX. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Mizuho decreased their price objective on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. The Goldman Sachs Group raised their price objective on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Finally, Stifel Nicolaus set a $45.00 price objective on shares of Syndax Pharmaceuticals in a research note on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $40.50.

Syndax Pharmaceuticals Trading Down 11.0%

Shares of NASDAQ:SNDX traded down $2.35 during trading on Friday, reaching $19.08. The company’s stock had a trading volume of 4,675,388 shares, compared to its average volume of 1,349,811. The company has a current ratio of 4.40, a quick ratio of 4.12 and a debt-to-equity ratio of 5.32. Syndax Pharmaceuticals has a 12 month low of $8.58 and a 12 month high of $25.59. The firm’s 50 day simple moving average is $23.03 and its two-hundred day simple moving average is $20.35. The stock has a market capitalization of $1.68 billion, a PE ratio of -5.80 and a beta of 0.41.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. The firm had revenue of $64.86 million during the quarter, compared to the consensus estimate of $69.76 million. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 216.23%. The firm’s revenue for the quarter was up 224.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.98) EPS. On average, research analysts predict that Syndax Pharmaceuticals will post -1.65 EPS for the current fiscal year.

Insider Activity at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the sale, the chief financial officer owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 17,159 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $360,853.77. Following the sale, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at $10,340,240.70. This represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,063 shares of company stock valued at $628,332 in the last ninety days. Insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Torray Investment Partners LLC increased its holdings in Syndax Pharmaceuticals by 7.2% during the first quarter. Torray Investment Partners LLC now owns 104,868 shares of the company’s stock valued at $2,450,000 after buying an additional 7,066 shares during the period. Hsbc Holdings PLC increased its holdings in Syndax Pharmaceuticals by 3.2% during the first quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock valued at $556,000 after buying an additional 730 shares during the period. Diversified Trust Co increased its holdings in Syndax Pharmaceuticals by 23.0% during the first quarter. Diversified Trust Co now owns 13,660 shares of the company’s stock valued at $319,000 after buying an additional 2,551 shares during the period. Invesco Ltd. increased its holdings in Syndax Pharmaceuticals by 20.6% during the fourth quarter. Invesco Ltd. now owns 160,525 shares of the company’s stock valued at $3,373,000 after buying an additional 27,434 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Syndax Pharmaceuticals during the fourth quarter valued at approximately $374,000.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $37 and upgraded SNDX to “overweight,” implying large upside versus the current price — a bullish analyst endorsement that can support the stock. Barclays Raises Price Target
• Positive Sentiment: Commercial traction: management reported strong product sales (Revuforj/revumenib net revenue ~$48.9M) and collaboration revenue tied to Niktimvo, driving total revenue up ~224% YoY — and the company highlighted upcoming real?world/frontline data in 2Q26 and Phase 2 topline readouts in 4Q26 (near-term catalysts). Syndax Q1 Results & Business Update
• Positive Sentiment: Earnings per share beat: reported loss of $0.48 vs. consensus loss of $0.59 — an improvement from last year and a metric that can temper downside from the revenue miss. Q1 EPS Beat Summary
• Neutral Sentiment: Earnings call transcript and slide deck are available for investors who want management color on commercial uptake and pipeline timelines. Earnings Call Transcript
• Neutral Sentiment: Quick analyst/press snapshots are circulating summarizing Q1 results and the conference call; useful for catching detail but less likely to move the stock alone. Q1 Earnings Snapshot
• Negative Sentiment: Revenue missed consensus ($64.9M reported vs. ~$69.8M expected), and the company still shows negative net margin/ROE and elevated leverage metrics noted in public filings — these mixed fundamentals likely pressured the stock despite the EPS beat and analyst upgrade. Revenue Miss & Financial Metrics

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.